Next report date
Report period
Q1 2024
EPS estimate
0.94TWD
Revenue estimate
599.00 MTWD
1.95TWD
198.41 MTWD
2.15 BTWD
80.97 M
About NANG KUANG PHARMACEUTICAL CO
Sector
CEO
Yue Pei Wang
Headquarters
Tainan
Website
Founded
1963
FIGI
BBG0015S6MF9
Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacture, process, and sale of western medicine and medical equipment. It specializes in eye drops, antibiotics, lozenges, solutions, powders, ointments, icing, citric acid, granules, sterile injection, gel, film-coated ingots, irrigation fluid, enteric-coated tablets, and frozen crystal injection. Its products include large volume parenterals, aseptic parenterals, lyophilized injection, pre-filled syringe, pre-mixed IV infusion bags, and oral suspensions. Nang Kuang Pharmaceutical was founded in February 1963 and is headquartered in Tainan, Taiwan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1752 is 44.55 TWD — it has decreased by 0.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TWSE exchange NANG KUANG PHARMACEUTICAL CO stocks are traded under the ticker 1752.
NANG KUANG PHARMACEUTICAL CO is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
1752 stock is 1.35% volatile and has beta coefficient of 0.31. Check out the list of the most volatile stocks — is NANG KUANG PHARMACEUTICAL CO there?
1752 earnings for the last quarter are 0.46 TWD per share, whereas the estimation was 0.81 TWD resulting in a −43.21% surprise. The estimated earnings for the next quarter are 0.77 TWD per share. See more details about NANG KUANG PHARMACEUTICAL CO earnings.
NANG KUANG PHARMACEUTICAL CO revenue for the last quarter amounts to 537.00 M TWD despite the estimated figure of 565.00 M TWD. In the next quarter revenue is expected to reach 571.00 M TWD.
Yes, you can track NANG KUANG PHARMACEUTICAL CO financials in yearly and quarterly reports right on TradingView.
1752 stock has fallen by 1.44% compared to the previous week, the month change is a 3.78% fall, over the last year NANG KUANG PHARMACEUTICAL CO has showed a 42.88% decrease.
1752 net income for the last quarter is −34.79 M TWD, while the quarter before that showed 46.62 M TWD of net income which accounts for −174.63% change. Track more NANG KUANG PHARMACEUTICAL CO financial stats to get the full picture.
Today NANG KUANG PHARMACEUTICAL CO has the market capitalization of 4.50 B, it has decreased by 1.56% over the last week.
Yes, 1752 dividends are paid annually. The last dividend per share was 2.30 TWD. As of today, Dividend Yield (TTM)% is 5.16%. Tracking NANG KUANG PHARMACEUTICAL CO dividends might help you take more informed decisions.
NANG KUANG PHARMACEUTICAL CO dividend yield was 3.75% in 2023, and payout ratio reached 101.80%. The year before the numbers were 3.60% and 65.99% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 1752 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NANG KUANG PHARMACEUTICAL CO stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NANG KUANG PHARMACEUTICAL CO technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NANG KUANG PHARMACEUTICAL CO stock shows the strong sell signal. See more of NANG KUANG PHARMACEUTICAL CO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NANG KUANG PHARMACEUTICAL CO EBITDA is 441.75 M TWD, and current EBITDA margin is 20.54%. See more stats in NANG KUANG PHARMACEUTICAL CO financial statements.